FibrosIX is a pre-clinical stage biotechnology start-up based in East Lansing, MI. Founded in 2016, the company is dedicated to preventing fibrosis through innovative therapeutics. They are developing proprietary small-molecule drugs that inhibit fibrotic disease by modulating a critical signaling pathway. Their lead drug candidate, FBX081, aims to prevent lung fibrosis in cancer patients induced by chemotherapy and radiation therapy.
FibrosIX's mission is to combat the thickening and scarring of connective tissue, known as fibrosis, which can lead to morbidity and contribute to a majority of deaths. With a focus on cutting-edge research and development, FibrosIX is working towards providing effective solutions for fibrotic diseases, particularly in the field of cancer treatment.
Generated from the website